Mutation Profiling of Uterine Lavage Fluid: Detection of Early Stage Endometrial Cancers
16 Jan 2017
This presentation, given at AMP 2016 by John Martignetti, MD, PhD, from the Laboratory of Translational Research, The Mount Sinai Hospital, discusses the development of a tool for the early detection of endometrial cancers. John Martignetti describes his research into developing the established Molecular Signature Method (MSM) into a diagnostic tool. The presentation covers the theory behind the method, results from a prospective study and the future directions of the research.
About the company
Swift Biosciences, Inc
Swift Biosciences opened its doors in February 2010 with a fully equipped laboratory facility in Ann Arbor, MI. The company is backed by experienced private investors. Multiple innovation platforms have been developed “in house” by a growing team of scientists and are covered by multiple patent applications.
Swift launched its first retail product in its myT® Primers platform, myT BRAF for detection of BRAF mutations, in February of 2012. The company is also working on additional products for mutation detection and gene sequencing, both internally and with partners.
Related products
Request Quote for All Products
Accel-Amplicon™ 56G Oncology Panel v2 (48 reactions)
Swift Biosciences, IncMultiplex amplicon panels for Illumina® platform.
